新型类风湿关节炎治疗药物托法替尼

Tofacitinib,a new drug for the treatment of rheumatoid arthritis

托法替尼是辉瑞公司开发的一种口服小分子Janus激酶(Janus kinase,JAK)抑制剂,于2012年11月获得美国FDA批准,用于治疗甲氨蝶呤反应不足或不耐受的中度至重度类风湿关节炎成年患者。本文对其药理作用、药动学、临床研究以及安全性等做一综述。

Tasocitinib is an oral small-molecule Janus kinase（JAK） inhibitor developed by Pfizer.In November 2012,Food and Drug Administration（FDA） has approved tasocitinib for the treatment of adults with moderately to severely active rheumatoid arthritis（RA） who have had an inadequate response or intolerance to methotrexate.The pharmacology,pharmacokinetics,clinical efficacy and safety of tofacitinib were reviewed in this paper.